Work

LBA67 Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Updated results from the phase III COSMIC-311 trial and prespecified subgroup analyses by prior therapy

Year: 2021

Type: conference-abstract

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.08.2148

Authors: J. Capdevila, B. Robinson, S.I. Sherman, B. Jarzab, C-C. Lin, F. Vaisman, A.O. Hoff, E. Hitre, D.W. Bowles, S. Sen, P. Patel, J. Oliver, B. Keam, M.S. Brose

Institutions: Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, The University of Sydney, The University of Texas MD Anderson Cancer Center, The Maria Sklodowska-Curie National Research Institute of Oncology, National Taiwan University Hospital, Instituto Nacional de Câncer - INCA, Universidade de São Paulo, Instituto do Câncer do Estado de São Paulo, University of Colorado Cancer Center, Exelixis (United States), Seoul National University Hospital, Abramson Cancer Center, University of Pennsylvania

Language: English

Topic: Thyroid Cancer Diagnosis and Treatment

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Roche, Sanofi, Handok, Exelixis, Eisai, Swedish Orphan Biovitrum, Ono Pharmaceutical, Ipsen, University of Texas MD Anderson Cancer Center, Ignyta, Daiichi Sankyo Europe

OpenAlex ID: W3201900523

Cites:

Cited by: 3

Related to: 10